MC002 not checked
Hangzhou MacroLink Biopharmaceutical LLC
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MC002 is a recombinant antibody-drug conjugate targeting the oncofetal antigen.A complete treatment cycle is defined as 21 calendar days. MC002 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle”In the company’s words, NCT07726212 on ClinicalTrials.gov
- Tested for
- Advanced Esophageal Cancer, Advanced Lung Cancer
- Main trialPhase 1
- “The goal of this clinical trial is to learn if ADC drug MC002 works to treat locally advanced/metastatic solid tumors in adults. It will also learn about the safety of MC002. The main questions it aims to answer are: Does participants tolerate the drug MC002 ? What medical problems do participants have when treating with MC002? Does participants benefit from the MC002 . Participants will: Intravenous infusion MC002 every 3 weeks in clinical Visit the clinic once every 3 weeks for checkups and tests Keep a diary of their symptoms”In the company’s words, NCT07726212 on ClinicalTrials.gov
Other drugs for Advanced Esophageal Cancer
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- DurvalumabAstraZeneca · Phase 3
- RilvegostomigAstraZeneca · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
Coming up1
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Dec 2027 | A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026